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INTRODUCTION
Asthma is a common and heterogeneous respiratory disease 
characterized by intermittent airway obstruction and respirato-
ry symptoms that are related to chronic airway inflammation 
and remodeling.
1 Pathological features of airway remodeling 
include goblet cell hyperplasia, subepithelial fibrosis, collagen 
deposition, mucosal gland hyperplasia, smooth muscle hyper-
trophy, and changes in the extracellular matrix.
1
Inflammation and remodeling are the main causes of airway 
hyperresponsiveness and chronic airway obstruction, charac-
teristic features of asthma. These changes are attributed to the 
altered expression of genes associated with transcriptional path-
ways, inflammatory processes, apoptosis, and cell prolifera-
tion.
2
However, the complex nature of the asthma phenotype, to-
gether with genetic heterogeneity and environmental influenc-
es, has made it difficult to uncover genetic aspects of this com-
mon condition.
3 Thus, the search for asthma-specific genes is 
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an important issue because such genes may promote the early 
detection, positive prognosis, and treatment of the disease. To 
this end, large-scale, high-throughput, whole-genome studies 
are needed to understand the genomic contribution to asthma.
Although many approaches have been used to investigate re-
lationships between diseases and genes, the high-throughput 
microarray is one of the most important. Microarray technology 
allows the monitoring of gene expression on a genomic scale. It 
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Purpose:  We sought to identify asthma-related genes and to examine the potential of these genes to predict asthma, based on expression lev-
els.  Methods:  The subjects were 42 asthmatics and 10 normal healthy controls. PBMC RNA was subjected to microarray analysis using a 35K ar-
ray; t-tests were used to identify genes that were expressed differentially between the two groups. A multiple logistic regression analysis was ap-
plied to the differentially expressed genes, and area under the curve (AUC) values from receiver operating characteristic (ROC) curves were obtained.
Results:  In total, 170 genes were selected using the following criteria: P≤0.001 and ≥2-fold change. Among these genes, 57 were up-regulated 
and 113 were down-regulated in asthmatics versus normal controls. A multiple logistic regression analysis was done using more stringent criteria 
(P≤0.001 and ≥5-fold change), and eight genes were selected as candidate asthma biomarkers. Using these genes, 255 models (2
8-1) were gener-
ated. Among them, only 85 showed P≤0.05 by multiple logistic regression analysis. Based on the AUCs from ROC curves for the 85 models, we 
found that the best model consisted of the genes MEPE, MLSTD1, and TRIM37. The model showed 0.9928 of the AUC with 98% sensitivity and 
80% specificity.  Conclusions:  MEPE, MLSTD1, and TRIM37 may be useful biomarkers for asthma.
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also enables the classification of genes causing various diseases 
and for a diagnosis to be made at the genetic level.
4,5
Several types of tissues have been used in human microarray 
studies of asthma, including airway epithelial cells and airway 
inflammatory cells from patients and healthy subjects.
6-10 Nasal 
mucosal cells are a good choice for genomic studies.
11
Although an analysis of gene expression in the airways can 
provide important information, obtaining airway tissues, in-
cluding airway epithelial cells, using bronchoalveolar lavage 
(BAL) or brushing is difficult, especially in severe asthma
12; thus, 
peripheral blood mononuclear cells (PBMCs) have been used 
as an alternative.
13-16 PBMCs contain lymphocytes, monocytes, 
and dendritic cells, which are recognized sources of allergic re-
sponse mediators.
Over the past decade, using gene expression profile analysis, 
the diagnosis of multifactorial complex diseases and their sub-
phenotypes have been attempted. Although the diagnostic val-
ue of the expression of a single gene is regarded as minimal, 
multi-gene analyses can increase the predictability, and possi-
bly lead to usable biomarkers.
In the present study, we identified candidate genes affecting 
asthma development using an mRNA expression chip. Addi-
tionally, we evaluated the diagnostic value of differential gene 
expression levels in the discrimination of asthmatics from nor-
mal controls through an additional analysis of the area under 
the curve (AUC) values from receiver operating characteristic 
(ROC) curves, sensitivity, and specificity.
17 Finally, the selected 
genes were analyzed according to asthma severity.
MATERIALS AND METHODS
Study subjects
The subjects were recruited from the Genome Research Cen-
ter for Allergy and Respiratory Diseases at Soonchunhyang 
University Hospital. All subjects were Korean. The protocol was 
approved by the local ethics committee of Soonchunhyang 
University Hospital. Written informed consent was obtained 
from all subjects.
All patients met the definition of asthma given in the Global 
Initiative for Asthma (GINA) guidelines.
1 Each patient showed 
airway reversibility, as documented by a positive bronchodila-
tor response of a greater than 15% increase in FEV1 and/or air-
way hyperreactivity to less than 10 mg/mL methacholine. Nor-
mal controls were recruited from hospital personnel; they gave 
negative answers to a screening questionnaire for respiratory 
symptoms and had an FEV1 ≥75% of the predicted value, a 
PC20 methacholine ≥10 mg/mL, and a normal chest X-ray.
Subjects were assessed using a skin-prick test for 24 common 
inhaled allergens, including house dust mites, Alternaria, As-
pergillus, pollen, dogs, cats, and cockroaches. Atopy was de-
fined as having a wheal reaction with the allergen extract equal 
to or greater than that with histamine (1 mg/mL) or 3 mm in di-
ameter. Total IgE was measured using the UniCAP system (Phar-
macia Diagnostics, Uppsala, Sweden). Peripheral venous blood 
was obtained when the subjects were in a stable state. No pa-
tient had an exacerbation or systemic steroid treatment within 
6 weeks of the study. Clinical profiles of the asthma patients and 
control subjects are summarized in Table 1.
cDNA synthesis and microarray hybridization
A human oligonucleotide microarrays (Genomictree Inc., 
Daejeon, Korea) containing 34,560 oligonucleotide probes, rep-
resenting human genes and gene transcripts, were used for gene 
expression analysis. The 34,560 oligoncleotide probes were pur-
chased from (Qiagen, Germantown, MD, USA). The synthesis 
of target cDNA probes and hybridization were performed ac-
cording to previously described.
8 Briefly, each 50 µg of total RNA 
was mixed with 2 µg of oligo-24N (dT) (GenoTech, Daejeon, 
Korea) in 15.4 µL of RNase free water and incubated at 65°C for 
10 minutes. After incubation, the single stranded cDNA was 
Table 1. Clinical profiles for asthma patients and normal controls, mild asthma and moderate to severe asthma subjects
Normal controls Asthmatics P value Mild asthma Moderate to 
severe asthma
P value
Number 10 42 30 12
Age (median [range], yr) 59 (48-78) 47 (21-70) 0.111 55 (32-78) 57 (28-77) 0.989
Male (%) 20.0 38.1 0.462 36.6 41.6 1.000
Smoking (NS/SM/ES) 8/1/1 29/7/6 1.000 23/4/2 6/3/3 0.332
Atopy (%) 30.0 54.7 0.291 40.0 96.6 0.004
FVC, % predicted 98.0±14.2 87.0±14.4 0.030 92.6±9.1 73.1±15.9 0.001
FEV1, % predicted 108.0±16.0 88.1±18.3 0.003 97.3±11.4 65.0±9.5 <0.001
PC20 methacholine (mg/mL) 25.0±0.0 9.0±10.4 <0.001 10.2±10.5 5.5±10.2 0.016
Body mass index (kg/m
2) 25.7±2.9 25.0±3.9 0.519 25.1±4.1 24.6±3.4 0.811
Log (total IgE concentration (IU/mL)) 1.6±0.5 2.1±0.5 1.000 2.0±0.6 2.4±0.4 0.018
Mild asthma and moderate to severe asthma are separated by FEV1 value of 80% predicted and P values were acquired by t-test or Fisher’s exact test.
NS, non-smoker; SM, smoker; ES, ex-smoker.Asthma-Predictive Genetic Markers in PBMC
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synthesized in the presence of Cy3-dUTP or Cy5-dUTP (1 mM 
each, NEN Life Science Products, Boston, MA, USA) at 42°C for 
2 hours. Total RNA from test samples and common reference 
RNA pooled from 10 normal samples were labeled with Cy5 
and Cy3, respectively. Both of Cy3 and Cy5-labeled cDNA were 
purified using PCR purification kit (Qiagen) as recommended 
by manufacturer. The purified cDNA was resuspended in 100 
µL of hybridization solution containing 5X SSC, 0.1% SDS, 30% 
formamide, 20 µg of Human Cot-1 DNA, 20 µg of poly A RNA 
and 20 µg of Yeast tRNA (Invitrogen, Grand Island, NY, USA). 
The hybridization mixtures were heated at 100°C for 2-3 min-
utes and directly pipetted onto microarrays. The arrays hybrid-
ized at 42°C for 12-16 hours in the humidified hybridization 
chamber (Genomictree Inc.). The hybridized miroarrays were 
washed with 2×SSC/0.1% SDS for 5 minutes, 0.1×SSC/0.1% 
SDS for 10 minutes, and 0.1×SSC for 2 minutes two times. The 
washed microarrays were immediately dried using the micro-
array centrifuge (Genomictree Inc.).
Statistical methods
For microarray analysis, background-corrected values for 
each probe on the BeadChip array were extracted using Bead-
Studio (Illumina, San Diego, CA, USA); P values were comput-
ed from the background model characterized by the chance 
that the target sequence signal was distinguishable from the 
negative controls on the same chip. Normalization was per-
formed for the extracted values. The statistical significance of 
the microarray data was calculated by t-tests using ‘R’ (ver. 2.8.1; 
http://www.r-project.org/). If the distribution of the mRNA ex-
pression levels showed normality and equality in the variances 
in each group (i.e., asthma and normal controls), a classic two-
sample t-test was used. If the distribution of mRNA expression 
levels showed normality and inequality in the variances for each 
group, the Welch two-sample t-test was used. If the distribution 
of mRNA expression levels did not show normality in each 
group, then the Mann-Whitney U-test was applied. For the di-
agnostic gene expression values used to discriminate the asth-
matics from the normal controls, we selected candidate genes 
with P<0.001 and a fold-change ≥5 between the two groups. 
Fold changes in gene expression were obtained by dividing the 
mean value for the asthmatics by that for the normal controls. 
After filtering by P value and fold-change, a power set was made 
using the candidate genes, and a multiple logistic regression 
analysis was performed with elements in the power set. ROC 
curves for all models were obtained and AUCs were calculat-
ed
19,20 to select disease marker genes.
 
RESULTS
Comparison of gene expression between the asthmatics and 
normal controls
To identify genes that may be related to asthma, we applied a 
high-throughput gene expression microarray consisting of 
15,054 featured genes on RNA samples, which were obtained 
from normal controls (n=10) and asthma patients (n=42). All 
values in the microarray cell were normalized and used for fea-
ture selection. The overall approach is depicted in Fig. 1.
To evaluate overall differences in gene expression levels in 
PBMCs between asthmatics and normal controls, we calculat-
ed gene expression as shown on a volcano plot. To identify dif-
ferentially expressed genes between the asthmatics and normal 
controls, we applied two types of t-tests and the Mann-Whitney 
U-test to the difference in mean expression level between the 
two groups. We selected genes having a P value<0.001 and a 
change of 2-fold or greater. Volcano plots of significance against 
the fold-change values for each gene in the PBMCs revealed 
that the expression levels were quite different between the asth-
matics and normal controls (Fig. 2A). Using the criteria of P≤
0.001 and a fold change ≥2, we identified 57 genes showing a 
significant increase in expression and 113 genes showing a sig-
nificant decrease in expression in the asthmatics compared 
with the normal controls (see Table S1 in additional file 1). A 
heat map of these differentially expressed genes (n=170) re-
vealed distinctive RNA expression profiles for the PBMCs (Fig. 
2B). The up- and down-regulated genes were well-classified by 
this hierarchical clustering method.
Because 170 genes would be too many to handle as biomark-
ers, we used the more stringent criteria of P≤0.001 and a fold 
change ≥5 to the differences in gene expression between the 
asthmatics and normal controls. Consequently, we identified 
eight genes (Fig. 3).
Development of genetic biomarkers for the diagnosis of 
bronchial asthma
The genes that met these criteria are listed in Table 2. The ex-
pression of ZFP161 and NOX5 was increased, while that of 
LMAN1, MEPE, MLSTD1, TRIM37, KNS2, and CCT5 was de-
All sample (n=52)
Humman Ref8 BeadChip (Illumina)(15054 genes)
Multiple logistics regression (compare ROCs using AUC)
Select gene(s) as the biomarker
Asthma group (n=42), control (n=10)  
Asthma/control>5.0 fold and P<0.001
Fig. 1. Gene expression profiling strategy and general workflow.Shin et al.
Allergy Asthma Immunol Res. 2011 October;3(4):265-272.  http://dx.doi.org/10.4168/aair.2011.3.4.265
Volume 3, Number 4, October 2011
268 http://e-aair.org
creased in the PBMCs of the asthmatics versus the normal con-
trols.
Selection of the best discriminative model using multiple 
logistic regression analysis and ROC curve analysis
Using the eight genes as candidate biomarkers to discriminate 
between asthmatics and normal controls, we performed a mul-
tiple logistic regression analysis for all elements of the power set 
and measured the AUCs from ROC curves. First, we made 255 
(2
8-1) models for all elements of the power set and measured 
the P values of the variable for each model. We separated the 
255 models into eight groups (Groups 1-8). Group n indicates 
models made of n genes for multiple logistic regression analy-
sis. Among the 255 models, only 85 showed P≤0.05. All data for 
the AUC and P values are presented in Supplementary Table S2 
(see additional file 2). As the number of genes increased, the P 
value decreased (Fig. 4). Only models comprising fewer than 
three genes showed significant P values (i.e., <0.05).
The AUC and ROC were calculated for Groups 1, 2, and 3. 
Among them, single genes or each combination of two or three 
genes having the five highest AUC values are presented in Fig. 
5A. The best AUC value (0.9928) was observed for a combina-
tion of three genes, MEPE, MLSTD1, and TRIM37 showing as-
ymptotic P values: 0.000001, asymptotic 95% confidence inter-
val (lower bound: 0.977, upper bound: 1). The ROC curves and 
AUC values for the other genes and combinations are present-
ed in Supplementary Figure S1 (see additional file 4).
Discriminating power of the combination of MEPE, MLSTD1, 
and TRIM37 between asthmatics and normal controls
To evaluate the discriminating power of the combination of 
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Fig. 3. Volcano graph. The x-axis represents the logarithm of the fold-change 
value, while the y-axis represents the negative logarithm of the P value. A and 
B denote areas satisfying the following criteria: ≥5-fold change and P≤0.001.
Table 2. List of genes meeting the criteria of P≤0.001 and a fold change of 
≥5-fold
Gene  P value Fold-change* Name
ZFP161 0.0004342765  8.09 Zinc finger protein 161 homolog 
NOX5 0.0000002402  5.60 NADPH oxidase, EF-hand calcium 
binding domain 
LMAN1 0.0000198657  0.19 Lectin, mannose-binding, 1
MEPE 0.0009997948  0.18 Matrix extracellular phosphogly-
coprotein
MLSTD1 0.0004841020  0.18 Fatty acyl CoA reductase 2
TRIM37 0.0000814375  0.16 Tripartite motif-containing 37 
KNS2 0.0001356000  0.15 Kinesin light chain 1
CCT5 0.0000014420  0.13 Chaperonin containing TCP1, 
subunit 5
*Fold change (asthma/normal control).Asthma-Predictive Genetic Markers in PBMC
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MEPE, MLSTD1, and TRIM37 between asthmatics and normal 
controls, we calculated the sensitivity and specificity using a 
contingency table of 42 asthmatics and 10 normal controls. As 
shown in Table 3, the sensitivity and selectivity were 0.98 and 
0.80, respectively, while the accuracy was 0.942. To evaluate the 
diagnostic accuracy of the three-gene combination in an inde-
pendent data set, we applied three-fold cross-validation (CV). 
The average results of three-fold CV for sensitivity, specificity, 
and accuracy were 1, 1, and 1, respectively.
Analysis of the selected genes according to asthma severity
We divided the asthma group into mild asthma and moder-
ate-to-severe asthma according to their FEV1% (threshold: 80), 
and we analyzed the genes for each paired group as follows: 
normal controls versus mild asthma, normal controls versus 
moderate-to-severe asthma, and mild asthma versus moder-
ate-to-severe asthma. By this analysis, we could predict genes 
involved in asthma development. Our complete results are pre-
sented in Supplementary Table S3 (see additional file 3). Table 4 
shows the results for the eight genes.
Based on our results, TRIM37 is predictive for the occurrence 
of asthma, while NOX5, LMAN1, KNS2, and MLSTD1 are pre-
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Fig. 5. (A) Values of the AUCs for each of the eight genes, two-gene combinations, and three-gene combinations. (B) ROC curve of the best model, consisting of 
MEPE, MLSTD1, and TRIM37 (P value: 0.000001; asymptotic 95% confidence interval lower bound: 0.977, upper bound: 1; AUC: 0.9928).
Table 3. Contingency table for the best model
Prediction 
outcome
Actual value
Sensitivity Specificity
Asthma Normal
Asthma 41 2
0.98 0.80 
Normal 1 8
*Fold change (asthma/normal control).Shin et al.
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dictive for mild asthma. CCT5 is predictive for moderate-to-se-
vere asthma.
DISCUSSION
We identified genes related to asthma using a microarray 
analysis of PBMCs. Using these data, we found that a combina-
tion of three genes, MEPE, MLSTD1, and TRIM37, showed the 
best discriminating power between asthmatics and normal 
controls. To our knowledge, this is the first reported study to se-
lect disease markers using ROC analyses of PBMCs. In our mi-
croarray analysis, when a P value threshold of <0.001 and a fold 
change of ≥2 were applied, a total 170 genes were selected. Of 
these genes, 57 were up-regulated and 113 were down-regulat-
ed in PBMCs. The genes included inflammatory and immune 
response genes, such as NOX5, MALT1, TNFRSF10C, GRK5, 
CXCL3, RELA, CD40, ABR, RELB, REBB2, PGLYRP1, CD82, 
RPE, CFTR, KITLG, and IKBKG, which would be expected to be 
expressed differentially in asthmatics versus normal controls. 
These findings suggested that our gene chip study was per-
formed adequately.
There have been several previous reports of gene expression 
analyses in asthma. Previous gene array studies have shown that 
CLCA1
21,22, SerpineB2
7,21,22, MUC5AC
6,21, AGR2
21, CPA3
6,22, and 
tryptase
6,22 are over-expressed in bronchial epithelial cells or the 
airway mucosa of asthmatics. Such studies have used tissues 
obtained from bronchial epithelial cells or the mucosa of 
healthy controls and subjects with allergic asthma. Genes such 
as NFκB p65 subunit (RELA) and scinderin (SCIN) were ex-
pressed at similar levels in our and these other studies, suggest-
ing that the expression of certain genes in the airways is reflect-
ed in the peripheral blood cells of similar subjects. However, 
many genes were expressed differently in the present study 
than in previous reports. This may be attributable to the differ-
ent tissue sources used, such as airways and peripheral blood 
cells. For mechanistic or pathogenesis studies, airway tissue, 
such as bronchial mucosa, would be the best target. However, 
obtaining airway tissues or airway epithelial cells using BAL or 
brushing is not convenient for asthmatics, especially those with 
severe asthma.
12 Thus, PBMCs were used for the development 
of diagnostic gene markers in the present study.
First, we narrowed the number of candidate gene markers 
from the 170 genes that were initially selected, because 170 
would be too many to handle. By applying more stringent crite-
ria (P<0.001 and ≥5-fold change), eight candidate genes were 
selected for modeling. Using these genes, a multiple logistic re-
gression analysis was performed to identify disease marker 
genes. Because we did not know the complex dependencies 
among the eight selected genes,
23 we made all 255 (2
8-1) possi-
ble models using the genes and measured the P values to ex-
amine their validity. ROC curves and the AUC were measured 
to assess the predictability of the gene markers for asthma.
Of the 255 models, only 85 showed a P value <0.05. Further-
more, the number of genes analyzed in combination was in-
versely correlated with the P values. Those models made of 
more than three genes showed insignificant statistics when a P-
value <0.05 was applied, so we compared the AUC values only 
for those genes or combinations of genes having P values <0.05. 
After performing a multiple logistic regression analysis, the best 
model (MEPE, MLSTD1, TRIM37) and the second best model 
(CCT5, MEPE, TRIM37) were found to show almost perfect 
classification. The AUC values were 0.9928 and 0.9904, respec-
tively. Considering that an AUC value of ‘1’ indicates perfect 
classification, 0.9928 and 0.9904 indicate very high predictabili-
ty for the markers. The sensitivity and selectivity for the best 
model were 0.98 and 0.80, respectively, while the accuracy was 
0.942. Thus, these models are sufficient to discriminate between 
asthmatics and normal controls. For three-fold CV, the results 
showed perfect classification. This means that the genes are 
very effective for independent data. Thus, the genes may be 
used as disease markers for asthma in PBMCs. The approach of 
selecting gene markers using ROC curves has been applied to 
select biomarkers in other diseases, including gastric cancer, 
knee osteoarthritis, and lung cancer.
24-26
In previous studies, the most up-regulated gene and/or down-
regulated gene have been selected and subjected to logistic re-
gression analyses and measurements of the AUC from ROC 
curves. However, such models might not have the best discrim-
inative performance as disease markers. In contrast, in the cur-
rent study, we selected several candidate genes that satisfied 
our criteria. We applied a multiple logistic regression analysis 
for all possible (2
8-1) models and selected the one with the 
highest AUC. In our experiment, a model consisting of three 
genes showed the best performance.
We also analyzed the eight genes selected according to asth-
ma severity. Our results show that TRIM37 was predictive of the 
occurrence of asthma, while NOX5, LMAN1, KNS2, and ML-
STD1 were predictive of mild asthma, and CCT5 was predictive 
of moderate-to-severe asthma.
Additionally, we analyzed the effect of asthma mediation on 
the expression levels of the three candidate genes. We found no 
difference in terms of mRNA level between the treated and un-
treated subjects using t-tests and multiple logistic regression 
analyses, indicating that there was no effect of mediation on the 
Table 4. The selected 8 genes analysis according to asthma severity
Group Num. Selected 8 genes
Normal controls vs. moder-
ate to severe asthma
Up: 22
Down: 31 TRIM37, CCT5
Normal controls vs. mild 
asthma
Up: 58 NOX5
Down: 106 TRIM37, LMAN1, KNS2, MLSTD1
Mild asthma vs. moderate 
to severe asthma
Up: 0
Down: 3Asthma-Predictive Genetic Markers in PBMC
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expression of the three genes.
To date, the functions of the genes used as diagnostic markers 
of asthma have not been characterized. MEPE is an inhibitor of 
mineralization in situ and in cell cultures where altered expres-
sion is associated with oncogenic osteomalacia and hypophos-
phatemic rickets. MLSTD1 is related to fatty alcohol synthesis 
in mammals.
27 CCT5 is associated with cell proliferation, the 
cell cycle, morphological changes, and apoptosis.
28 TRIM37 en-
codes a member of the tripartite motif (TRIM) family, which is 
involved in diverse cellular functions, such as developmental 
patterning and oncogenesis. We searched various databases to 
determine any relationship between asthma and the selected 
genes; however, we were unable to find any connection. Thus, 
the functional relation of these genes with asthma remains to 
be solved; however, these genes do highlight the complex 
mechanism(s) underlying the pathogenesis of asthma. Further-
more, they comprise a set of potential biomarkers for use in dis-
criminating between asthmatics and normal individuals. The 
three genes presented here as biomarkers were selected by 
computational methods alone. Additional functional studies 
are needed to determine the exact mechanism or indirect rela-
tionship among these genes with asthma.
In summary, a 35K whole-genome mRNA expression study of 
PBMCs from asthmatics and normal controls resulted in the se-
lection of 170 genes based on criteria of P≤0.001 and a fold 
change ≥2. By applying more stringent criteria (P≤0.001 and a 
fold change ≥5), we selected eight genes as candidate asthma 
biomarkers. Using the AUCs from ROC curves, we identified a 
genetic biomarker consisting of three genes (MEPE, MLSTD1, 
TRIM37) having a diagnostic accuracy of 0.9928 AUC, with 98% 
sensitivity and 80% specificity. This marker may prove to be 
useful diagnostically after validation using a larger number of 
samples.
ADDITIONAL FILES
Additional file 1 - Table S1, Excel file, 170 genes (P≤0.001 and 
fold change ≥2).
Additional file 2 - Table S2, Excel file, 255 models (AUC, P-val-
ue).
Additional file 3 - Table S3, Excel file, gene list according to 
asthma severity.
Additional file 4 - Figure S1, PowerPoint file, ROC curves and 
AUCs for all models.
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